SCP
NUVB icon

SymBiosis Capital Partners’s Nuvation Bio NUVB Stock Holding History

SymBiosis Capital Partners’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,250,000
Closed -$11.2M – 9
2025
Q4 		$11.2M Buy
+1,250,000
New +$7.74M 10.23% 6

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SymBiosis Capital Partners's NUVB Position: Q1 2026 in Review

SymBiosis Capital Partners sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 1,250,000 shares — an estimated $11.2M sold.

SymBiosis Capital Partners first reported a position in NUVB in Q4 2025 and held it in 1 quarter. The position peaked at $11.2M in Q4 2025. 233 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • SymBiosis Capital Partners reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
  • SymBiosis Capital Partners sold 1,250,000 Nuvation Bio shares in Q1 2026, an estimated $11.2M.
  • SymBiosis Capital Partners first reported a position in Nuvation Bio in Q4 2025 and held it in 1 quarter.
  • SymBiosis Capital Partners's Nuvation Bio position peaked at $11.2M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.